Exploring further policy options suggested in the report Pharmaceutical Innovation and access to medicines, the OECD has undertaken, with the financial support of the EU Health Programme, several projects to further identify avenues to increase pharmaceutical expenditure efficiency and better prepare to changes in the market.
This project aims to describe best practices in the use of information routinely collected in health systems to improve knowledge on the performance of medicines in real settings and increase spending efficiency. It is based on research, a survey of OECD and EU countries, and interviews.
The Analytical Report and the Country Notes were released on February 28, 2019:
This project aims to help countries better anticipating dynamics in pharmaceutical markets (new entrants, end of market/data exclusivity). It is based on research, a country survey, and interviews.
The final Report and the Country Notes were released on April 30, 2019:
In many OECD and EU countries, medicines are largely financed by government or compulsory health insurance schemes. Coverage and pricing decisions are made at the central level and sometimes entail a negotiation with pharmaceutical companies. The negotiators’ objectives are to pay for value within their budget constraints but they are unequally equipped to achieve this results. This project mainly consisted of experience-sharing and a review of the experience with performance-based managed entry agreements. A 2-day capacity building workshop, bringing together negotiators from healthcare payers in OECD countries and EU member states with consultants, industry experts and academics, was held in 2018. The final Report on OECD work on performance-based managed entry agreements was published on 16 December 2019.
The increasing prevalence of cancer represents a significant and growing burden worldwide. While advances in prevention, early detection, and treatment have led to improved survival, the rapid introduction of new oncology medicines has raised concerns about the ability to provide and sustain affordable access, even among the wealthiest countries around the globe. This project aims to review the current state of access to oncology medicines in OECD and EU countries, and explore the policies and practices adopted by countries to address a number of challenges specific to oncology medicines. It is based on the results of research, a survey of OECD and EU countries, and a two-day workshop. The Analytical Report was released on April 14, 2020.